While we show that AAV6 delivered CXCL9 transgene expression predominantly emanates from tumor-reactive astrocytes, our scRNAseq data shows that each anti-PD-1 and AAV gene therapy induces CXCL9 transcription within CD8 T cells (Fig. 7g), additionally demonstrating immune activation as a result of treatment17,18,56. This evidence concerns the gene CD8A and neoplasm.